Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2026-03-02 @ 11:09 PM
Study NCT ID:
NCT02790320
Status:
COMPLETED
Last Update Posted:
2016-06-03
First Post:
2016-05-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer
Sponsor:
Eisai Farmacêutica S.A.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
OBU-SW-H-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None